Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth.
Proteomic-based drug testing is an emerging approach to establish the clinical value and anti-neoplastic potential of multikinase inhibitors. The multikinase inhibitor midostaurin (PKC412) is a promising new agent used to treat patients with advanced systemic mastocytosis (SM). We examined the target interaction profiles and the mast cell (MC)-targeting effects of two pharmacologically relevant midostaurin metabolites, CGP52421 and CGP62221. All three compounds, midostaurin and the two metabolites, suppressed IgE-dependent histamine secretion in basophils and MC with reasonable IC(50) values. Midostaurin and CGP62221 also produced growth inhibition and dephosphorylation of KIT in the MC leukemia cell line HMC-1.2, whereas the second metabolite, CGP52421, which accumulates in vivo, showed no substantial effects. Chemical proteomic profiling and drug competition experiments revealed that midostaurin interacts with KIT and several additional kinase targets. The key downstream regulator FES was recognized by midostaurin and CGP62221, but not by CGP52421 in MC lysates, whereas the IgE receptor downstream target SYK was recognized by both metabolites. Together, our data show that the clinically relevant midostaurin metabolite CGP52421 inhibits IgE-dependent histamine release, but is a weak inhibitor of MC proliferation, which may have clinical implications and may explain why mediator-related symptoms improve in SM patients even when disease progression occurs.
Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria.|Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
B
B
Peter
Center for Molecular Medicine (CeMM) of the Austrian Academy of Sciences, Vienna, Austria.
G E
GE
Winter
Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
K
K
Blatt
Center for Molecular Medicine (CeMM) of the Austrian Academy of Sciences, Vienna, Austria.
K L
KL
Bennett
Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
G
G
Stefanzl
Center for Molecular Medicine (CeMM) of the Austrian Academy of Sciences, Vienna, Austria.|H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
U
U
Rix
Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria.
G
G
Eisenwort
Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria.|Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
E
http://orcid.org/0000-0001-7409-4204
E
Hadzijusufovic
Center for Molecular Medicine (CeMM) of the Austrian Academy of Sciences, Vienna, Austria.
M
M
Gridling
Novartis Oncology, Basel, Switzerland.
C
C
Dutreix
Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
G
G
Hoermann
Third Medical Department Mannheim, University of Heidelberg, Mannheim, Germany.
J
J
Schwaab
Division of Clinical Haematology, Guy's Hospital, London, UK.
D
D
Radia
Novartis Oncology, Basel, Switzerland.
J
J
Roesel
Novartis Oncology, Basel, Switzerland.
P W
PW
Manley
Third Medical Department Mannheim, University of Heidelberg, Mannheim, Germany.
A
A
Reiter
Center for Molecular Medicine (CeMM) of the Austrian Academy of Sciences, Vienna, Austria.
G
G
Superti-Furga
Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria.|Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
P
P
Valent
D000328:Adult; D000368:Aged; D001491:Basophils / Q000187:drug effects / Q000502:physiology; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D005260:Female; D006636:Histamine Release / Q000187:drug effects; D006801:Humans; D008297:Male; D008407:Mast Cells / Q000187:drug effects* / Q000502:physiology; D008415:Mastocytosis / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D019009:Proto-Oncogene Proteins c-kit / Q000378:metabolism; D019311:Staurosporine / Q000031:analogs & derivatives* / Q000494:pharmacology
C586021:CGP 52421; C586020:CGP 62221; D047428:Protein Kinase Inhibitors; D019009:Proto-Oncogene Proteins c-kit; D019311:Staurosporine; C059539:midostaurin